<?xml version="1.0" encoding="UTF-8"?>	<item><status>past</status><description>&lt;p&gt;&lt;span style="color : #000000"&gt;&lt;strong&gt;Using Systems Biology to "Fast-Track" Development and Approval of Novel&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style="color : #000000"&gt;&lt;strong&gt;Therapeutics and Diagnostics&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="color : #704525"&gt;&lt;span style="color : #704525"&gt;&lt;span&gt;When: Thursday, June 21st, 2012, 10:00 am - 11:30 am.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style="color : #704525"&gt;&lt;span&gt;Where: Boston Convention &amp;amp; Exhibition Center&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;Overview of Systems Biology and how its application can determine more precisely and quickly which biomarkers are relevant to specific diseases for diagnosis or therapeutic intervention. This approach can also determine subgroups or different genotypes within these diseases in developing a diagnostic test that will determine whether a patient will respond to a specific drug with minimal side effects.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;Drugs can now be targeted for a specific set of patients resulting in higher efficacy. In return, the FDA requirements for the number of patients required for the phase I-III trials may be smaller, the cost and time for R&amp;amp;D will be reduced and the approval time will be shorter.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;Moderator:&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;1) Regina Au, MBA, MIM - Principal, Strategic Marketing Consultant at BioMarketing Insight&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;Speakers:&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;1) David E. Hill, PhD - Research Scientist in Cancer Biology and Associate Director of the Center for Cancer Systems Biology (CCSB) at the Dana-Farber Cancer Institute (DFCI).&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;2) Glenn Miller, PhD - Vice President / Head of Personalized Medicine, Astra Zeneca&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;3) Steven Tregay, PhD - Founder, President, and CEO of Forma Therapeutics&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;4) FDA Speaker - TBD&lt;/span&gt;&lt;/p&gt;
&lt;span&gt;For details on the session and speakers go to &lt;a target="_blank"&gt;http://biomarketinginsight.com/Events.htm&lt;/a&gt;&lt;/span&gt;</description><event_hosts><event_hosts_item><member_name>Joshua Lang</member_name><member_id>3926861</member_id></event_hosts_item></event_hosts><maybe_rsvp_count>0</maybe_rsvp_count><waitlist_count>0</waitlist_count><updated>1340299546000</updated><rating><average>0.0</average><count>0</count></rating><group><who>Scientific Members</who><join_mode>open</join_mode><urlname>nexusproject</urlname><id>1294865</id><group_lat>42.3699989319</group_lat><group_lon>-71.0999984741</group_lon><name>Nexus Project</name></group><yes_rsvp_count>4</yes_rsvp_count><created>1333500575000</created><visibility>public</visibility><name>Using Systems Biology to "Fast-Track" Development and Approval of Novel</name><id>59151142</id><headcount>0</headcount><utc_offset>-14400000</utc_offset><time>1340287200000</time><event_url>http://www.meetup.com/nexusproject/events/59151142/</event_url></item>